SCHEMBL891962

SCHEMBL891962

CCCCCOC(=O)Nc1ccn([C@]2(O)O[C@H](COC(C)=O)[C@@H](O)[C@@]2(C)O)c(=O)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
PKM P14618 1/20 0.32
ALDH1A1 P00352 2/20 0.32
GSTA2 P09210 2/20 0.31
GSTP1 P09211 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
GSTM1 P09488 1/20 0.31
P2RY2 P41231 1/20 0.31
CSNK2A2 P19784 1/20 0.31
CSNK2A1 P68400 1/20 0.31
RAB9A P51151 3/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
NPC1 O15118 2/20 0.31
CYP1A2 P05177 2/20 0.31
CYP2C19 P33261 2/20 0.31
MAPT P10636 1/20 0.31
NFKB1 P19838 1/20 0.31
STAT1 P42224 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL891694 0.93 LMNA (0.38) LMNAPRMT5WDR77PKMALDH1A1
SCHEMBL891166 0.91 LMNA (0.40) LMNAPRMT5WDR77PKMALDH1A1
SCHEMBL891938 0.86 LMNA (0.36) LMNAPRMT5WDR77PKMALDH1A1
SCHEMBL891602 0.85 POLB (0.34)
SCHEMBL891868 0.85 LMNA (0.36) LMNAPRMT5WDR77PKMALDH1A1
SCHEMBL891584 0.82 LMNA (0.36) LMNAPRMT5WDR77PKMALDH1A1
SCHEMBL891685 0.81 POLB (0.34)
SCHEMBL891439 0.80 POLB (0.35) RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL891780 0.79 POLB (0.33)
SCHEMBL891653 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF XENOPORT, INC. (US) 2012-04-05 US claimed
US-8058260-B2 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof XENOPORT, INC. (US) 2011-11-15 US claimed
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof XENOPORT, INC. 2007-11-22 US claimed
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF XENOPORT, INC. (US) 2012-04-05 US disclosed
US-8058260-B2 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof XENOPORT, INC. (US) 2011-11-15 US disclosed
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof XENOPORT, INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MTAP, NSUN2, CDA LMNA 1243/4885PRMT5 123/4885WDR77 790/4885
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof MTAP, NSUN2, PAICS LMNA 1214/4885PRMT5 130/4885WDR77 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.